Psoriatic arthritis (PsA) is a type of inflammatory joint disease that may get worse over time, resulting in severe joint damage and disability. Even though PsA was first distinguished as a unique disorder in 1964 by the American College of Rheumatology, it was only recently that the disease became highly recognized as a standalone disease by the medical community, partially due to increased research interest and patient advocacy efforts. Physicians on the front lines of treating PsA expect that the diagnosed cases of PsA will increase in the future due to improved diagnosis and disease awareness.
The disease is considered to be rare in the general population, but is much more common in people with the skin disease psoriasis. The epidemiology of PsA varies globally, with the highest prevalence rates seen in the US and Europe, and the lowest rates in Asia. This is mostly due to differences in underlying genetic factors.
Go deeper with GlobalData
There are also variations in the disease’s diagnosis rate, a measure of how well a disease can be clinically recognized. Market research of key opinion leaders reported that the diagnosis rate of PsA was below 50% in the US and as low as 30% in Europe in 2015. However, it is projected that the diagnosis rates will reach upwards of 70% in some markets by 2025. GlobalData epidemiologists estimated, as a result of increasing diagnosis rate, that the number of diagnosed prevalent cases of PsA will increase in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) over the next 10 years by close to 500,000 cases. The figure below presents the expected changes in the diagnosed prevalent cases of PsA in the 7MM from 2015–2025.
The changing epidemiology of the disease is likely to have a positive impact on the pharmaceutical sales in this sector as more patients receive a diagnosis and seek treatment. By the end of 2025, GlobalData estimates that PsA therapeutic sales will increase to over $12.58 billion, which includes three pipeline therapies and the launch of biosimilars. The single most important driver of growth in the PsA marketplace will be the increase in diagnosed prevalent cases.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
